On this page
- Quick reference
- Dosage chart and four steps
- Supplies needed
- Peptide Reconstitution Simulator
- Vial and research context
- GHK-Cu at a Glance
- 100 mg Vial Dosing Calculations
- GHK-Cu Storage and Handling
- GHK-Cu Research Evidence by Route
- How GHK-Cu Works in Laboratory Research
- GHK-Cu vs GHK: Why Copper Binding Matters
- 100 mg GHK-Cu Vial Calculations
- Human GHK-Cu Skin and Wound Research
- Injectable GHK-Cu: Safety and Evidence Limits
- Injection Technique and Research Records
- GHK-Cu Frequently Asked Questions
- Important Research Note
- References
- Related research, protocols, and guides
GHK-Cu Quick Reference (100 mg Vial)
- Vial contents
- 100 mg GHK-Cu
- Final volume
- 3 mL
- Concentration
- 33.33 mg/mL
- One U-100 unit
- 333.33 mcg in 0.01 mL
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read GHK-Cu Peptide: Benefits, Uses, Side Effects, Dosage, and Research.
GHK-Cu Dosage Chart
Dosing & Reconstitution Guide
Educational guide for reconstitution and common dosing patterns
Standard / Conservative Approach (3 mL = 33.33 mg/mL; 5 days/week)
| Week/Phase | Dose per Injection | Units (per injection) (mL) |
|---|---|---|
| Weeks 1-4 | 1.0 mg (1000 mcg) | 3 units (0.03 mL) |
| Weeks 5-8 | 1.5 mg (1500 mcg) | 4.5 units (0.045 mL) |
| Weeks 9-12+ | 2.0 mg (2000 mcg) | 6 units (0.06 mL) |
Frequency: Once daily, 5 days per week, progressing from 1.0 mg to 1.5 mg and then 2.0 mg as shown above. At 33.33 mg/mL, those doses equal 3, 4.5, and 6 U-100 units. Use a U-100 syringe with markings that clearly display every value in the table.
Reconstitution Steps
- Draw 3.0 mL of the protocol-specified sterile diluent with a sterile syringe.
- Add it slowly down the vial wall to reduce foaming.
- Gently swirl or roll until dissolved. Do not shake.
- Label the vial with the 33.33 mg/mL concentration, preparation date, and storage instructions.
Alternative Protocol (3 mL = 33.33 mg/mL; 3 times weekly)
| Week/Phase | Dose per Injection | Units (per injection) (mL) |
|---|---|---|
| Weeks 1-12+ | 2.0 mg (2000 mcg) | 6 units (0.06 mL) |
Frequency: 2.0 mg three times per week, such as Monday, Wednesday, and Friday. At 33.33 mg/mL, each injection equals 6 U-100 units (0.06 mL), for approximately 6 mg per week.
Supplies Needed
Plan based on an 8-16 week protocol. Calculations are shown for both the 5 days/week and 3 times/week schedules.
-
Peptide Vials (GHK-Cu, 100 mg each):
- 5 days/week (1.0-2.0 mg/day):
- 8 weeks (~50 mg total): 1 vial
- 12 weeks (~90 mg total): 1 vial
- 16 weeks (~130 mg total): 2 vials
- 3 times/week (2 mg each):
- 8 weeks (~48 mg total): 1 vial
- 12 weeks (~72 mg total): 1 vial
- 16 weeks (~96 mg total): 1 vial
-
Insulin Syringes (U-100, 29-31 gauge):
- 5 days/week:
- Per week: 5 syringes
- 8 weeks: 40 syringes
- 12 weeks: 60 syringes
- 16 weeks: 80 syringes
- 3 times/week:
- Per week: 3 syringes
- 8 weeks: 24 syringes
- 12 weeks: 36 syringes
- 16 weeks: 48 syringes
-
Sterile or Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for the displayed calculation.
- 1 vial: 3 mL
- 2 vials: 6 mL
- 3 vials: 9 mL
-
Alcohol Swabs: Two administration swabs per injection: one for the vial stopper and one for the injection site.
- 5 days/week:
- Per week: 10 swabs
- 8 weeks: 80 swabs or 1 x 100-count box
- 12 weeks: 120 swabs or 2 x 100-count boxes
- 16 weeks: 160 swabs or 2 x 100-count boxes
- 3 times/week:
- Per week: 6 swabs
- 8 weeks: 48 swabs or 1 x 100-count box
- 12 weeks: 72 swabs or 1 x 100-count box
- 16 weeks: 96 swabs or 1 x 100-count box
Planning note: Peptide and water totals are arithmetic minimums based on the listed schedule. Follow the handling and discard limits for the exact products used.
Peptide Reconstitution Simulator
Practice preparing this vial with the verified strength and final volume from this protocol.
GHK-Cu Vial and Research Context
- Reconstitute: Prepare the 100 mg vial to a final volume of 3.0 mL for a concentration of 33.33 mg/mL.
- Research protocol range: The tables below cover 1.0 mg, 1.5 mg, and 2.0 mg using the standard and alternative research-use schedules.
- Easy measuring: At 33.33 mg/mL, 1 U-100 unit = 0.01 mL = approximately 333.3 mcg.
- Quick conversions: 1.0 mg = 3 units, 1.5 mg = 4.5 units, and 2.0 mg = 6 units.
GHK-Cu, or glycyl-L-histidyl-L-lysine copper complex, is a naturally occurring copper peptide studied for collagen-related pathways, tissue remodeling, antioxidant defense, and skin repair[7][8]. This 100 mg GHK-Cu protocol focuses on strength-specific concentration, U-100 syringe calculations, route-specific evidence, and the limits of injection research.
GHK-Cu at a Glance
This 100 mg peptide protocol keeps vial concentration, U-100 syringe units, frequency, supplies, and evidence limits together.
- Compound: GHK-Cu, a copper-binding tripeptide also called copper tripeptide-1.
- Vial calculation: 100 mg prepared to 3.0 mL equals 33.33 mg/mL.
- Displayed amounts: 1.0 mg, 1.5 mg, and 2.0 mg per administration.
- U-100 conversion: 3, 4.5, and 6 units respectively.
- Evidence boundary: Human research is mainly topical or wound-formulation research, not controlled parenteral dosing research.
100 mg Vial Dosing Calculations
The primary chart converts each research amount directly into milligrams, milliliters, and U-100 syringe markings.
- Standard model: 1.0 mg or 3 units, 1.5 mg or 4.5 units, and 2.0 mg or 6 units across the displayed phases.
- Alternative model: 2.0 mg or 6 units, three times weekly.
- Weekly context: The alternative schedule totals 6 mg per week.
- Community-reported use: These subcutaneous schedule examples describe practice patterns; they are not clinically validated standards or recommendations.
- Calculation rule: Dose volume equals the selected mass divided by 33.33 mg/mL; U-100 units equal milliliters multiplied by 100.
GHK-Cu Storage and Handling
Storage and stability depend on the exact formulation, diluent, container, sterility controls, and batch documentation.
- Dry material: Follow the vial and batch instructions for temperature, light, and moisture protection.
- Prepared solution: Follow product-specific refrigerated storage and discard instructions; vial strength alone does not establish a universal beyond-use period.
- Handling: Minimize light exposure and avoid unnecessary freeze-thaw cycles.
- Recordkeeping: Label the vial with the 33.33 mg/mL concentration, preparation date, storage condition, and applicable discard date.
GHK-Cu Research Evidence by Route
GHK-Cu research is not interchangeable across topical, wound-care, local, and systemic routes. Published human studies have primarily examined topical creams, gels, serums, skin penetration, and wound-care formulations[1][2][3][4][5]. Local administration in an animal wound model adds preclinical context, but it does not validate a human subcutaneous GHK-Cu dose[6].
The tables on this page are therefore calculation examples for a 100 mg vial. No controlled human trial has established an approved dosing schedule for injected GHK-Cu, an injection frequency, a cycle length, or a systemic benefit. Route, formulation, concentration, and population must remain explicit whenever the evidence is interpreted.
How GHK-Cu Works in Laboratory Research
GHK-Cu is a naturally occurring copper peptide formed when the tripeptide glycyl-L-histidyl-L-lysine binds copper. Reviews describe GHK-Cu research involving extracellular-matrix signaling, antioxidant and anti-inflammatory pathways, collagen-related activity, tissue repair, and gene-expression patterns[7]. Experimental work also reports GHK-related modulation of matrix metalloproteinase-2, an enzyme involved in matrix remodeling[8].
Research on GHK-Cu describes a network of biological effects rather than one switch. In laboratory research, GHK-Cu acts as a copper-binding complex; GHK-Cu signals have been studied in matrix regulation; and GHK-Cu influences gene-expression patterns. Reviews discuss how GHK-Cu supports tissue-remodeling research. The shorthand claim that GHK-Cu works by stimulating one isolated target is too narrow because multiple interacting processes are described[7][8]. Those mechanisms help explain why research on this copper peptide often focuses on skin structure, wound healing, collagen, and remodeling. Any claim about GHK-Cu benefits must still be matched to route, formulation, and study design. They do not by themselves establish that an injected GHK-Cu preparation works for a particular clinical outcome, nor do they determine a recommended dose.
GHK-Cu vs GHK: Why Copper Binding Matters
GHK is a peptide made from three amino acids: glycine, histidine, and lysine. GHK-Cu is the same peptide bound to a copper ion. In research terminology, GHK-Cu is a copper-bound complex and a copper-binding peptide; the phrase GHK-Cu copper peptide distinguishes the complex from unbound GHK.
The peptide was identified in human plasma, and more than 50 years of research have explored GHK-Cu gene expression, collagen synthesis, collagen production, extracellular-matrix activity, and tissue remodeling[7][8]. GHK-Cu is a copper peptide with broad laboratory interest, but mechanistic findings do not establish a clinical dose or prove that a specific administration route is effective.
100 mg GHK-Cu Vial Calculations
Preparing a 100 mg vial to 3.0 mL produces 33.33 mg/mL. On a U-100 syringe, one unit equals 0.01 mL, so one unit contains approximately 0.333 mg, or 333.3 mcg, of GHK-Cu.
- 1.0 mg dose: 1.0 ÷ 33.33 = 0.03 mL = 3 U-100 units.
- 1.5 mg dose: 1.5 ÷ 33.33 = 0.045 mL = 4.5 U-100 units.
- 2.0 mg dose: 2.0 ÷ 33.33 = 0.06 mL = 6 U-100 units.
The larger vial changes concentration and supply planning; it does not make a higher GHK-Cu dose more appropriate. A 50mg GHK-Cu vial can require a different conversion, so the unit values from one vial setup should not be transferred to another. The syringe marking must be recalculated whenever vial mass or final volume changes.
How much GHK-Cu is in each unit? At this concentration, each unit contains about 0.333 mg. Dosage ranges found in online discussions do not replace route-specific evidence. The important dosage considerations are vial mass, final volume, concentration, measured dose, and frequency; peptide dosing arithmetic does not establish a recommended regimen.
Human GHK-Cu Skin and Wound Research
Human evidence includes a diabetic-ulcer study of a topical copper peptide formulation, a postoperative topical study after carbon-dioxide laser resurfacing, comparative cream research, a split-face GHK-Cu serum and copper peptide serum study, and human-skin penetration work[1][2][3][4][5]. Published human studies used GHK-Cu in topical copper peptide products. These studies are relevant to topical delivery and wound formulations, not to the subcutaneous schedule in the chart. The formulation studies measured outcomes related to skin quality and collagen and elastin; they do not establish improved skin from injections.
An ongoing Phase 2 study is evaluating topical GHK-Cu gel for acute skin-wound healing[9]. FDA records also include a topical Iamin Gel wound-dressing device, which is route- and product-specific and should not be interpreted as approval of a GHK-Cu injection[12].
Injectable GHK-Cu: Safety and Evidence Limits
No injectable formulation of GHK-Cu has an established FDA-approved human dosing regimen. FDA compounding materials identify potential safety concerns for injections containing GHK-Cu and note that available human safety information is limited[10]. FDA 503A materials also treat route as part of the substance evaluation, reinforcing that topical findings cannot be converted into a systemic injection schedule[11].
Possible risks can depend on sterility, endotoxin control, concentration, excipients, copper exposure, injection technique, and individual health factors. A calculation can show how much material is in a syringe; it cannot prove safety, efficacy, or suitability for human use.
The phrase GHK-Cu peptide therapy appears in consumer searches, but no approved GHK-Cu therapy or medically validated peptide protocol is established. GHK-Cu administration on this page is calculation context only. It does not instruct readers to combine GHK-Cu, build a GHK-Cu stack, or treat this page as a medically supervised peptide therapy guide. Claims that GHK-Cu has a strong safety profile for injection are not supported by robust injectable human data, and current evidence does not show that injected GHK-Cu accelerates healing in humans. A syringe calculation does not determine whether or how to inject GHK-Cu. Likewise, a GHK-Cu injection search result is not evidence of safety or effectiveness.
Injection Technique and Research Records
General subcutaneous technique references are included only for measurement, aseptic handling, site rotation, and disposal context[15][16][17].
- Use new sterile equipment for each preparation or administration.
- Allow skin antiseptic to dry and follow the written protocol for site, angle, and device[16].
- Rotate and document sites rather than repeatedly using one location[15].
- Record the dose, concentration, volume, date, batch identifier, and site.
- Dispose of used sharps immediately in an appropriate container[17].
GHK-Cu Frequently Asked Questions
These frequently asked questions separate vial calculations from what the research can actually support.
What is GHK-Cu?
GHK-Cu is a copper-binding tripeptide, also called copper tripeptide-1. It is studied in skin, extracellular-matrix, collagen, gene-expression, and tissue-repair research[7][8].
What does a 100 mg GHK-Cu vial change?
Vial strength changes concentration, syringe units, and supply totals. With a 3.0 mL final volume, the concentration is 33.33 mg/mL. It does not change the evidence supporting a dose.
How many U-100 units equal 1 mg of GHK-Cu?
At 33.33 mg/mL, 1 mg equals 0.03 mL or 3 U-100 units. This conversion applies only to the 100 mg vial prepared to exactly 3.0 mL.
Is there a clinically established daily injection dose for GHK-Cu?
No controlled human trial has established a clinically approved daily dose for an injected GHK-Cu preparation. The chart displays community-reported use examples and arithmetic conversions, not medical recommendations.
Can topical research support a GHK-Cu injection schedule?
No. Topical skin and wound-healing studies provide formulation-specific evidence, but they do not validate subcutaneous dose, frequency, cycle length, or systemic outcomes[1][5].
Is there a standard GHK-Cu dosage?
No standard GHK-Cu dosage is established for injection. Common GHK-Cu dosing claims and dosage ranges should not be treated as validated clinical guidance.
What about GHK-Cu for hair?
Skin and hair searches often connect GHK-Cu with hair growth, hair loss, microneedling, and the phase of the hair cycle. GHK-Cu hair claims and cosmetic peptide claims require formulation-specific evidence. The sources cited on this page do not establish an injected dose for those outcomes, and this chart should not be read as a treatment protocol.
Is injectable GHK-Cu FDA approved?
No FDA-approved injection dosing regimen for GHK-Cu is established. FDA compounding materials discuss potential risks and limited human safety information for injection use of GHK-Cu[10][11].
Important Research Note
This page is for educational and research purposes only. It does not provide medical advice, diagnose or treat disease, establish a recommended human dose, or replace professional clinical judgment.
References
Research References
- 1Mulder GD, et al. Wound Repair and Regeneration. Human diabetic-ulcer study of topical glycyl-L-histidyl-L-lysine copper.
- 2Miller TR, et al. Archives of Facial Plastic Surgery. 2006. Topical copper tripeptide complex after carbon-dioxide laser resurfacing.
- 3Abdulghani AA, et al. 1998. Comparative topical-cream study including a copper-binding peptide preparation.
- 4Badenhorst T, et al. 2016. Split-face GHK-Cu nano-serum study of collagen, elastin, and wrinkle-related outcomes.
- 5Hostynek JJ, et al. Inflammation Research. 2010. Final human-skin penetration paper for a GHK-Cu preparation.
- 6Maquart FX, et al. Journal of Clinical Investigation. 1993. Local GHK-Cu exposure in a rat wound-chamber model.
- 7Pickart L, Margolina A. International Journal of Molecular Sciences. 2018. Review of regenerative and gene-expression research involving GHK-Cu.
- 8Maquart FX, et al. 2000. GHK-related modulation of matrix metalloproteinase-2 expression.
- 9ClinicalTrials.gov. NCT07437586. Ongoing Phase 2 study of topical GHK-Cu gel for acute skin-wound healing.
- 10U.S. Food and Drug Administration. Compounding safety-risk information that includes injection use of GHK-Cu.
- 11U.S. Food and Drug Administration. 503A Categories Update. Route-specific bulk-substance evaluation context for GHK-Cu.
- 12U.S. Food and Drug Administration. 510(k) K953853. Iamin Gel topical wound-dressing device record.
Additional Technical and Protocol Sources
- 15Roswell Park Comprehensive Cancer Center. General self-injection preparation, site rotation, and disposal guidance.
- 16Centers for Disease Control and Prevention. Current subcutaneous injection technique job aid.
- 17World Health Organization, NCBI Bookshelf. Best practices for injections and related procedures.
Related research, protocols, and guides
Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.
Research overview
Other vial-strength protocols
Related protocols and comparisons